🎉 M&A multiples are live!
Check it out!

aTyr Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for aTyr Pharma and similar public comparables like Julphar, Vivoryon Therapeutics, and Benevolent AI.

aTyr Pharma Overview

About aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.


Founded

2005

HQ

United States of America
Employees

59

Website

atyrpharma.com

Financials

LTM Revenue $0.7M

LTM EBITDA -$69.3M

EV

$209M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

aTyr Pharma Financials

aTyr Pharma has a last 12-month revenue of $0.7M and a last 12-month EBITDA of -$69.3M.

In the most recent fiscal year, aTyr Pharma achieved revenue of $0.2M and an EBITDA of -$66.4M.

aTyr Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See aTyr Pharma valuation multiples based on analyst estimates

aTyr Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.4M $0.2M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$52.2M -$66.4M XXX XXX XXX
EBITDA Margin -14781% -28244% XXX XXX XXX
Net Profit -$45.3M -$50.4M XXX XXX XXX
Net Margin -12844% -21442% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

aTyr Pharma Stock Performance

As of April 15, 2025, aTyr Pharma's stock price is $3.

aTyr Pharma has current market cap of $267M, and EV of $209M.

See aTyr Pharma trading valuation data

aTyr Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$209M $267M XXX XXX XXX XXX $-0.82

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

aTyr Pharma Valuation Multiples

As of April 15, 2025, aTyr Pharma has market cap of $267M and EV of $209M.

aTyr Pharma's trades at 278.3x LTM EV/Revenue multiple, and -3.0x LTM EBITDA.

Analysts estimate aTyr Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for aTyr Pharma and 10K+ public comps

aTyr Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $209M XXX XXX XXX
EV/Revenue 887.8x XXX XXX XXX
EV/EBITDA -3.1x XXX XXX XXX
P/E -4.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -3.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get aTyr Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

aTyr Pharma Valuation Multiples

aTyr Pharma's NTM/LTM revenue growth is 1154%

aTyr Pharma's revenue per employee for the last fiscal year averaged $4K, while opex per employee averaged $1.2M for the same period.

Over next 12 months, aTyr Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate aTyr Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for aTyr Pharma and other 10K+ public comps

aTyr Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -33% XXX XXX XXX XXX
EBITDA Margin -28244% XXX XXX XXX XXX
EBITDA Growth 27% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -27090% XXX XXX XXX XXX
Revenue per Employee $4K XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 5863% XXX XXX XXX XXX
R&D Expenses to Revenue 23137% XXX XXX XXX XXX
Opex to Revenue 29000% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

aTyr Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

aTyr Pharma M&A and Investment Activity

aTyr Pharma acquired  XXX companies to date.

Last acquisition by aTyr Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . aTyr Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by aTyr Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About aTyr Pharma

When was aTyr Pharma founded? aTyr Pharma was founded in 2005.
Where is aTyr Pharma headquartered? aTyr Pharma is headquartered in United States of America.
How many employees does aTyr Pharma have? As of today, aTyr Pharma has 59 employees.
Who is the CEO of aTyr Pharma? aTyr Pharma's CEO is Dr. Sanjay S. Shukla, M.D.,M.S..
Is aTyr Pharma publicy listed? Yes, aTyr Pharma is a public company listed on NAS.
What is the stock symbol of aTyr Pharma? aTyr Pharma trades under ATYR ticker.
When did aTyr Pharma go public? aTyr Pharma went public in 2015.
Who are competitors of aTyr Pharma? Similar companies to aTyr Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of aTyr Pharma? aTyr Pharma's current market cap is $267M
What is the current revenue of aTyr Pharma? aTyr Pharma's last 12-month revenue is $0.7M.
What is the current EBITDA of aTyr Pharma? aTyr Pharma's last 12-month EBITDA is -$69.3M.
What is the current EV/Revenue multiple of aTyr Pharma? Current revenue multiple of aTyr Pharma is 278.3x.
What is the current EV/EBITDA multiple of aTyr Pharma? Current EBITDA multiple of aTyr Pharma is -3.0x.
What is the current revenue growth of aTyr Pharma? aTyr Pharma revenue growth between 2023 and 2024 was -33%.
Is aTyr Pharma profitable? Yes, aTyr Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.